The POISE-3 study assessed the effects of a hypotension-avoidance strategy versus a hypertension-avoidance strategy in patients undergoing noncardiac surgery. touchCARDIO spoke to Dr Maura Marcucci (McMaster University, Hamilton, Ontario, Canada) to discuss her presentation of the results of the POSE-3 study at the American College of Cardiology Annual Meeting 2022.
- Could you give us a brief overview of the clinical burden of hypotension in noncardiac surgery? 010:15-01:17
- What were the aims and design of the POISE-3 blood pressure study? 021:17-03:03
- What were the results of the study? 03:03-04:46
- How would the results contribute to knowledge and practice? 04:46-06:06
Speaker Disclosure: Maura Marcucci has received grant and research support from the Canadian Institutes of Health Research, National Health and Medical Research Council (Australia) and Research Grant Council (Hong Kong SAR, China).
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!